Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

American Journal of Hematology

Volumn 89, Issue 12, 2014, Pages 1159-1160

  Landgren, Ola ^a   Gormley, Nicole ^b   Turley, Danielle ^b   Owen, Roger G ^c   Rawstron, Andy ^c   Paiva, Bruno ^d   Barnett, David ^e   Arroz, Maria ^f   Wallace, Paul ^g   Durie, Brian ^h   Yuan, Constance ^a   Dogan, Ahmet ⁱ   Stetler Stevenson, Maryalice ^a   Marti, Gerald E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c St James's Institute of Oncology   (United Kingdom)

^d UNIVERSITY OF NAVARRA   (Spain)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f Centro Hospitalar de Lisboa Ocidental   (Portugal)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW; CONSENSUS; DIAGNOSTIC VALUE; DRUG RESPONSE; FLOW CYTOMETRY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; STANDARDIZATION; GENETICS; MORTALITY; NEOPLASM, RESIDUAL; ORGANIZATION; PATHOLOGY; SURVIVAL; UTILIZATION;

TUMOR MARKER;

CONGRESSES AS TOPIC; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920580293     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23831     Document Type: Letter

References (8)

1. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012;119:687-691.
2. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540-2547.
3. Roschewski M, Korde N, Wu SP, Landgren O. Pursuing the curative blueprint for early myeloma. Blood 2013;122:486-490.
4. FDA-NCI Roundtable: Symposium on Flow Cytometry Detection of Minimal Residual Disease in Multiple Myeloma. 2014. Available from: http://www.fda.gov/medicaldevices/newsevents/workshopsconferences/ucm402038.htm. Last accessed [June 26, 2014].
5. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801-1809.
6. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-4023.
7. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123:3073-3079.
8. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011;118:5989-5995.